Why the study?
Does cilostazol added to dual antiplatelet therapy reduce MACCE and restenosis in patients with bare metal stents?
Does cilostazol added to dual antiplatelet therapy reduce MACCE and restenosis in patients with bare metal stents?
Adding cilostazol to standard dual antiplatelet therapy significantly reduces restenosis and target lesion revascularization after bare metal stent implantation without increasing bleeding risk.
No takes yet. Share an insight, caveat, or question.
Supports cilostazol addition to DAPT after bare-metal stenting; confirms reduced restenosis and TLR in this RCT.
Chen et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: